Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €4.51 EUR
Change Today +0.039 / 0.87%
Volume 11.3K
VSC On Other Exchanges
Symbol
Exchange
Xetra
OTC US
As of 5:59 AM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

4sc ag (VSC) Snapshot

Open
€4.56
Previous Close
€4.47
Day High
€4.65
Day Low
€4.46
52 Week High
04/8/15 - €7.75
52 Week Low
03/10/15 - €3.00
Market Cap
82.9M
Average Volume 10 Days
28.7K
EPS TTM
€-0.90
Shares Outstanding
18.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for 4SC AG (VSC)

Related News

No related news articles were found.

4sc ag (VSC) Related Businessweek News

No Related Businessweek News Found

4sc ag (VSC) Details

4SC AG researches and develops small-molecule drugs for the treatment of cancer and autoimmune diseases. The company operates through two segments, Development and Discovery & Collaborative Business. Its product portfolio in the area of autoimmune diseases includes Vidofludimus, an oral small-molecule drug candidate, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The company’s product portfolio in the area of oncology comprises Resminostat, an oral pan-histone-deacetylase inhibitor, which is in Phase II and Phase I clinical trials for the treatment of hepatocellular carcinoma, Hodgkin’s lymphoma, colorectal cancer, non-small-cell lung cancer, and solid tumors; 4SC-202, an epigenetic anti-cancer compound that has completed Phase I clinical trial for the treatment of hematological tumors; and 4SC-205, an anti-cancer compound, which has completed Phase I clinical trial for the treatment of solid tumors. It also conducts research programs in the areas of cancer immunotherapy, cancer stem cells, epigenetics, cytokine modulation, and ion channel blockers for the treatment of autoimmune, inflammatory eye, and oncology diseases. The company was founded in 1997 and is headquartered in Martinsried, Germany.

58 Employees
Last Reported Date: 05/7/15
Founded in 1997

4sc ag (VSC) Top Compensated Officers

Chairman of Management Board, Chief Executive...
Total Annual Compensation: €273.0K
Co-Founder, Chief Scientific Officer, Chief D...
Total Annual Compensation: €209.0K
Compensation as of Fiscal Year 2014.

4sc ag (VSC) Key Developments

4SC AG Presents at BioEquity Europe 2015, May-19-2015 through May-20-2015

4SC AG Presents at BioEquity Europe 2015, May-19-2015 through May-20-2015. Venue: InterContinental Vienna, Vienna, Austria. Presentation Date & Speakers: May-19-2015. May-20-2015, Enno Spillner, Chairman of Management Board, Chief Executive Officer and Chief Financial Officer.

4SC AG Reports Consolidated Financial Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Year 2015

4SC AG reported consolidated financial results for the first quarter ended March 31, 2015. For the quarter, the company’s consolidated revenue was EUR 1.99 million against EUR 1.44 million a year ago. The increase in revenue was mainly due to allocations to Yakult Honsha of costs to produce the resminostat compound. The company's result from operating activities (EBIT) improved by 37% to negative EUR 1.33 million in the first quarter of 2015, primarily on the back of higher revenue. The company reported negative EBIT of 2.12 million in the year 2014. The loss for the period decreased by 27% to EUR 1.54 million against EUR 2.12 million reported in the year 2014. Earnings per share improved to negative EUR 0.03 against negative EUR 0.04 a year ago. Cash from operations amounted to EUR 0.70 million in the reporting period against EUR 0.71 million a year ago. For 2015, the Management Board anticipates a slight decrease in research and development costs and a further reduction in the consolidated net loss from operations as against 2014 as a result of a renewed drop in operating expenses and a rise in the contributions to earnings at the same time. This is, however, contingent on the company's research and development programmes and partnerships continuing to exist and running according to plan and no new clinical studies being started. The company expects to continue posting annual net losses in the short to medium term. For 2015, the Management Board expects the company’s research subsidiary to generate a positive cash flow from operations.

4SC AG, Q1 2015 Earnings Call, May 07, 2015

4SC AG, Q1 2015 Earnings Call, May 07, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VSC:GR €4.51 EUR +0.039

VSC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VSC.
View Industry Companies
 

Industry Analysis

VSC

Industry Average

Valuation VSC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.1x
Price/Book 91.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact 4SC AG, please visit www.4sc.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.